Oruka Therapeutics (NASDAQ:ORKA) Shares Down 6.4% – Time to Sell?

Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA) dropped 6.4% during trading on Friday . The stock traded as low as $59.55 and last traded at $59.52. Approximately 309,504 shares traded hands during mid-day trading, a decline of 49% from the average daily volume of 610,010 shares. The stock had previously closed at $63.60.

Wall Street Analyst Weigh In

ORKA has been the topic of several analyst reports. Leerink Partners upped their target price on Oruka Therapeutics from $58.00 to $86.00 and gave the company an “outperform” rating in a report on Monday, March 16th. Weiss Ratings restated a “sell (d-)” rating on shares of Oruka Therapeutics in a report on Thursday, January 22nd. BTIG Research restated a “buy” rating and set a $73.00 price target on shares of Oruka Therapeutics in a report on Friday, March 13th. Stifel Nicolaus increased their price target on Oruka Therapeutics from $47.00 to $72.00 and gave the stock a “buy” rating in a report on Friday, March 13th. Finally, Wall Street Zen upgraded Oruka Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, March 16th. Ten equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Oruka Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $64.90.

Oruka Therapeutics Stock Performance

The stock has a market capitalization of $2.95 billion, a P/E ratio of -32.03 and a beta of -0.54. The business has a fifty day simple moving average of $39.53 and a 200-day simple moving average of $32.19.

Oruka Therapeutics (NASDAQ:ORKA) last posted its quarterly earnings results on Thursday, March 12th. The company reported ($0.45) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.61) by $0.16. On average, sell-side analysts anticipate that Oruka Therapeutics, Inc. will post -3.41 earnings per share for the current year.

Insiders Place Their Bets

In related news, insider Joana Goncalves sold 7,641 shares of the stock in a transaction on Monday, March 16th. The stock was sold at an average price of $40.91, for a total value of $312,593.31. Following the transaction, the insider directly owned 33,377 shares in the company, valued at $1,365,453.07. This trade represents a 18.63% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Lawrence Otto Klein sold 1,729 shares of the stock in a transaction on Monday, March 16th. The stock was sold at an average price of $41.30, for a total value of $71,407.70. Following the completion of the transaction, the chief executive officer owned 927,309 shares in the company, valued at approximately $38,297,861.70. This represents a 0.19% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 23,765 shares of company stock worth $849,575. 24.69% of the stock is owned by company insiders.

Hedge Funds Weigh In On Oruka Therapeutics

Large investors have recently modified their holdings of the company. Legal & General Group Plc bought a new position in shares of Oruka Therapeutics in the 2nd quarter worth $28,000. BNP Paribas Financial Markets lifted its holdings in shares of Oruka Therapeutics by 464.0% in the 2nd quarter. BNP Paribas Financial Markets now owns 2,803 shares of the company’s stock worth $31,000 after purchasing an additional 2,306 shares in the last quarter. Royal Bank of Canada lifted its holdings in shares of Oruka Therapeutics by 47.2% in the 4th quarter. Royal Bank of Canada now owns 1,139 shares of the company’s stock worth $34,000 after purchasing an additional 365 shares in the last quarter. Los Angeles Capital Management LLC bought a new position in shares of Oruka Therapeutics in the 4th quarter worth $37,000. Finally, PNC Financial Services Group Inc. bought a new position in shares of Oruka Therapeutics in the 3rd quarter worth $39,000. 56.44% of the stock is currently owned by institutional investors.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.